相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients
Alvaro Diaz-Gonzalez et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
Technical progress in circulating tumor DNA analysis using next generation sequencing
Yunfei Bai et al.
MOLECULAR AND CELLULAR PROBES (2020)
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma A Phase 2 Clinical Trial
Andrea Cercek et al.
JAMA ONCOLOGY (2020)
Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
Fangda Li et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Chennianci Zhu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
Elaine Kilgour et al.
CANCER CELL (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Sara Massironi et al.
CELLS (2020)
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
R. Bahleda et al.
ANNALS OF ONCOLOGY (2020)
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Shalini Makawita et al.
FUTURE ONCOLOGY (2020)
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Sakti Chakrabarti et al.
CANCERS (2020)
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Arvind Dasari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
Angela Lamarca et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
Raluca Maria Fostea et al.
CANCERS (2020)
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience
Giovanni Brandi et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2020)
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives
Alessandro Rizzo et al.
CANCER GENOMICS & PROTEOMICS (2020)
HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma
Dante Lamberti et al.
HEPATOLOGY (2019)
Molecular Pathogenesis of Cholangiocarcinoma
Peter L. Labib et al.
BMC CANCER (2019)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda et al.
CLINICAL CANCER RESEARCH (2019)
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
Joon Oh Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
Chiara Raggi et al.
AMERICAN JOURNAL OF PATHOLOGY (2019)
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma
Amit Mahipal et al.
CANCER TREATMENT REVIEWS (2019)
LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
G K Abou-Alfa et al.
ANNALS OF ONCOLOGY (2019)
Biliary Tract and Primary Liver Tumors Who, What, and Why?
Alan W. Hemming
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
Melanie A. Krook et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma
Brian K. Chung et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Emerging molecular target antagonists for the treatment of biliary tract cancer
Pasquale Lombardi et al.
EXPERT OPINION ON EMERGING DRUGS (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
BGJ398 for FGFR-altered advanced cholangiocarcinoma
Judith A. Gilbert
LANCET ONCOLOGY (2018)
Liver transplantation for intrahepatic cholangiocarcinoma
David D. Lee et al.
LIVER TRANSPLANTATION (2018)
Novel targeted treatment options for advanced cholangiocarcinoma
Amit Mahipal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Emerging molecular therapeutic targets for cholangiocarcinoma
Sumera Rizvi et al.
JOURNAL OF HEPATOLOGY (2017)
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Jharna Datta et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Imatinib Changed Everything
Dan L. Longo
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma
Elizabeth C. Smyth et al.
CANCER DISCOVERY (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
Staging of intrahepatic cholangiocarcinoma
Sean M. Ronnekleiv-Kelly et al.
HEPATOBILIARY SURGERY AND NUTRITION (2017)
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K. P. Papadopoulos et al.
BRITISH JOURNAL OF CANCER (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. W. Valle et al.
ANNALS OF ONCOLOGY (2016)
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein
Yu Wang et al.
CANCER LETTERS (2016)
Liver Transplantation for Very Early Intrahepatic Cholangiocarcinoma: International Retrospective Study Supporting a Prospective Assessment
G. Sapisochin et al.
HEPATOLOGY (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Dysregulated FGF signalling in neoplastic disorders
Yasmine Tanner et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence G. Hall et al.
PLOS ONE (2016)
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Sumera Rizvi et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
Mitesh J. Borad et al.
CURRENT OPINION IN GASTROENTEROLOGY (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma
Tomoki Shirota et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
Lipika Goyal et al.
ONCOLOGIST (2015)
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Andrew X. Zhu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
Ming-Huang Chen et al.
ONCOTARGET (2014)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad et al.
PLOS GENETICS (2014)
Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study
Shoaib Rafi et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2013)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
D. Sia et al.
ONCOGENE (2013)
Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma
H-X Xu et al.
BRITISH JOURNAL OF RADIOLOGY (2012)
Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers
Sarwa Darwish Murad et al.
GASTROENTEROLOGY (2012)
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success
Thomas J. Vogl et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Shahid A. Khan et al.
JOURNAL OF HEPATOLOGY (2012)
Radiofrequency Ablation in the Management of Unresectable Intrahepatic Cholangiocarcinoma
Ying Fu et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Radiofrequency Ablation for the Treatment of Primary Intrahepatic Cholangiocarcinoma
Jin Hyoung Kim et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2011)
Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience
Francesco Antonio Polistina et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Adjuvant Transcatheter Arterial Chemoembolization for Intrahepatic Cholangiocarcinoma after Curative Surgery: Retrospective Control Study
W. F. Shen et al.
WORLD JOURNAL OF SURGERY (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Stereotactic body radiotherapy for unresectable cholangiocarcinoma
Neil Kopek et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Genetic and Epigenetic Heterogeneity in Cancer: A Genome-Centric Perspective
Henry H. Q. Heng et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
The FGF family: biology, pathophysiology and therapy
Andrew Beenken et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution
Michelle L. DeOliveira et al.
ANNALS OF SURGERY (2007)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
分享论文
